A Phase 2 interventional study of diazepam nasal spray in Epilepsy, sponsored by Acorda Therapeutics. Terminated at 33 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-07-30.
Sponsored by Acorda Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing diazepam in Epilepsy — none open to participants now, none under way, none of them phase 3. Diazepam · Epilepsy.
Among the 10 studies testing diazepam in Epilepsy, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 2, and was the 5th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →None of the 10 studies testing diazepam in Epilepsy is open now. The open studies under Epilepsy, anywhere →
Diazepam: first FDA approval 1963 (VALIUM). What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 3
First in 1995; this study’s year is marked. 1 started in 2014.
This study's enrollment of 126 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 68 across the 10 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
Acorda Therapeutics is the lead sponsor of 38 studies on the registry; none are open to participants now.
Acorda Therapeutics has 3 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing diazepam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
Drug: diazepam nasal spray
One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
Drug: diazepam nasal spray
Olfactory Changes as Measured by the Smell Identification Test (SIT)
The SIT is a 50-item multiple-choice standardized test of olfactory function. Scoring of the test in the ability to smell ranges from normal (Normosmia: score 35 - 40 Women; 34 - 40 Men); to inability to smell (Anosmia score 6 - 18); or Malingering (not engaged in the test) ranges 0 - 5.
Time frame: Screening, weeks 12, 24, 36, 48 and 51
Change From Baseline (Screening) in Nasal Mucosa.
Change from baseline treatment visits using a focused nasal exam was based on a scale of nasal irritation "none" to Grade 4 "septal perforation."
Time frame: Screening, Weeks 12, 24, 36, 48 and 51
Change in Taste as Measured by a Taste Change Questionnaire
Change in taste questionnaire was administered to subjects at every study visit only if the subject complained of a change in taste or as needed to report a related AE. The taste change profile included sweet, salty, sour, bitter, oily, sharp, chalky, metallic. The subject rated the change on a 10-point scale ranging from a weak change (1) to very strong (10).
Time frame: Weeks 12, 24
Adolescents or adults who have refractory epilepsy (drug resistant epilepsy per Kwan 2010) with a history of cluster seizures, also known as multiple episodes of acute repetitive seizures, for which acute treatment with a benzodiazepine was indicated as part of the standard of care or an individualized rescue treatment plan.
| Milestone | DZNS - Adolescents (Ages 12 - 15) | DZNS - Adults (Ages 16 - 65) |
|---|---|---|
| Started | 9 | 99 |
| Completed | 0 | 13 |
| Not completed | 9 | 86 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 9 |
| Withdrew: Noncompliance with study drug | 0 | 3 |
| Withdrew: Withdrawn due to termination by sponsor | 7 | 67 |
The SIT is a 50-item multiple-choice standardized test of olfactory function. Scoring of the test in the ability to smell ranges from normal (Normosmia: score 35 - 40 Women; 34 - 40 Men); to inability to smell (Anosmia score 6 - 18); or Malingering (not engaged in the test) ranges 0 - 5.
| Participants | Diazepam Nasal Spray (Adults) | Diazepam Nasal Spray (Adolescents) |
|---|---|---|
| Screening — Normosmia | 18 | 0 |
| Screening — Mild Microsmia | 15 | 1 |
| Screening — Moderate Microsmia | 8 | 3 |
| Screening — Severe Micromisia | 7 | 1 |
| Screening — Anosmia | 9 | 0 |
| Screening — Probable Malingering | 0 | 0 |
| Week 12 — Normosmia | 6 | 0 |
| Week 12 — Mild Microsmia | 16 | 0 |
| Week 12 — Moderate Microsmia | 9 | 1 |
| Week 12 — Severe Micromisia | 1 | 2 |
| Week 12 — Anosmia | 2 | 0 |
| Week 12 — Probable Malingering | 0 | 0 |
| Week 24 — Normosmia | 5 | 0 |
| Week 24 — Mild Microsmia | 9 | 0 |
| Week 24 — Moderate Microsmia | 2 | 0 |
| Week 24 — Severe Micromisia | 5 | 0 |
| Week 24 — Anosmia | 0 | 0 |
| Week 24 — Probable Malingering | 0 | 0 |
| Week 36 — Normosmia | 2 | 0 |
| Week 36 — Mild Microsmia | 6 | 0 |
| Week 36 — Moderate Microsmia | 4 | 0 |
| Week 36 — Severe Micromisia | 1 | 0 |
| Week 36 — Anosmia | 1 | 0 |
| Week 36 — Probable Malingering | 0 | 0 |
| Week 48 — Normosmia | 0 | 0 |
| Week 48 — Mild Microsmia | 5 | 0 |
| Week 48 — Moderate Microsmia | 1 | 0 |
| Week 48 — Severe Micromisia | 3 | 0 |
| Week 48 — Anosmia | 1 | 0 |
| Week 48 — Probable Malingering | 0 | 0 |
| Week 51 — Normosmia | 1 | 0 |
| Week 51 — Mild Microsmia | 3 | 0 |
| Week 51 — Moderate Microsmia | 1 | 0 |
| Week 51 — Severe Micromisia | 4 | 0 |
| Week 51 — Anosmia | 1 | 0 |
| Week 51 — Probable Malingering | 0 | 0 |
Change from baseline treatment visits using a focused nasal exam was based on a scale of nasal irritation "none" to Grade 4 "septal perforation."
| Participants | Adults | Adolescents |
|---|---|---|
| Screening : Nasal Irritation None | 67 | 6 |
| Screening : Nasal Irritation Grade 1a | 10 | 1 |
| Screening : Nasal Irritation Grade 1b | 3 | 0 |
| Screening : Nasal Irritation Grade 2 | 0 | 0 |
| Screening : Mucosal Edema None | 71 | 6 |
| Screening : Mucosal Edema Mild | 9 | 1 |
| Screening : Nasal Discharge None | 66 | 6 |
| Screening : Nasal Discharge Mild | 14 | 1 |
| Screening : Mucosal Erythema None | 65 | 5 |
| Screening : Mucosal Erythema Mild | 13 | 2 |
| Screening : Mucosal Erythema Moderate | 2 | 0 |
| Screening : Mucosal Bleeding/Epistaxis None | 79 | 6 |
| Screening : Mucosal Bleeding/Epistaxis Mild | 1 | 1 |
| Screening : Crusting of Mucosa None | 77 | 7 |
| Screening : Crusting of Mucosa Mild | 3 | 0 |
| Week 12 : Nasal Irritation None | 50 | 4 |
| Week 12 : Nasal Irritation Grade 1a | 5 | 0 |
| Week 12 : Nasal Irritation Grade 1b | 3 | 0 |
| Week 12 : Nasal Irritation Grade 2 | 1 | 0 |
| Week 12 : Mucosal Edema None | 55 | 3 |
| Week 12 : Mucosal Edema Mild | 4 | 1 |
| Week 12 : Nasal Discharge None | 49 | 4 |
| Week 12 : Nasal Discharge Mild | 10 | 0 |
| Week 12 : Mucosal Erythema None | 39 | 4 |
| Week 12 : Mucosal Erythema Mild | 20 | 0 |
| Week 12 : Mucosal Erythema Moderate | 0 | 0 |
| Week 12 : Mucosal Bleeding/Epistaxis None | 58 | 4 |
| Week 12 : Mucosal Bleeding/Epistaxis Mild | 1 | 0 |
| Week 12 : Crusting of Mucosa None | 58 | 4 |
| Week 12 : Crusting of Mucosa Mild | 1 | 0 |
| Week 24: Nasal Irritation None | 37 | 1 |
| Week 24: Nasal Irritation Grade 1a | 1 | 0 |
| Week 24: Nasal Irritation Grade 1b | 1 | 0 |
| Week 24: Mucosal Edema None | 35 | 0 |
| Week 24: Mucosal Edema Mild | 4 | 1 |
| Week 24: Nasal Discharge None | 31 | 1 |
| Week 24: Nasal Discharge Mild | 8 | 0 |
| Week 24: Mucosal Erythema None | 33 | 1 |
| Week 24: Mucosal Erythema Mild | 6 | 0 |
| Week 24: Mucosal Bleeding/Epistaxis None | 39 | 1 |
| Week 24: Crusting of Mucosa None | 37 | 1 |
| Week 24: Crusting of Mucosa Mild | 2 | 0 |
| Week 36: Nasal Irritation None | 21 | 1 |
| Week 36: Nasal Irritation Grade 1a | 1 | 0 |
| Week 36: Mucosal Edema None | 21 | 0 |
| Week 36: Mucosal Edema Mild | 1 | 1 |
| Week 36: Nasal Discharge None | 20 | 1 |
| Week 36: Nasal Discharge Mild | 1 | 0 |
| Week 36: Mucosal Erythema None | 20 | 1 |
| Week 36: Mucosal Erythema Mild | 2 | 0 |
| Week 36: Mucosal Bleeding/Epistaxis None | 22 | 1 |
| Week 36: Crusting of Mucosa None | 21 | 1 |
| Week 36: Crusting of Mucosa Mild | 1 | 0 |
| Week 48: Nasal Irritation None | 12 | 0 |
| Week 48: Nasal Irritation Grade 1a | 1 | 0 |
| Week 48: Mucosal Edema None | 13 | 0 |
| Week 48: Nasal Discharge None | 13 | 0 |
| Week 48: Mucosal Erythema None | 13 | 0 |
| Week 48: Mucosal Bleeding/Epistaxis None | 13 | 0 |
| Week 48: Crusting of Mucosa None | 13 | 0 |
| Week 51: Nasal Irritation None | 13 | 0 |
| Week 51: Mucosal Edema None | 13 | 0 |
| Week 51: Nasal Discharge None | 12 | 0 |
| Week 51: Nasal Discharge Mild | 1 | 0 |
| Week 51: Mucosal Erythema None | 13 | 0 |
| Week 51: Mucosal Bleeding/Epistaxis None | 13 | 0 |
| Week 51: Crusting of Mucosa None | 13 | 0 |
Change in taste questionnaire was administered to subjects at every study visit only if the subject complained of a change in taste or as needed to report a related AE. The taste change profile included sweet, salty, sour, bitter, oily, sharp, chalky, metallic. The subject rated the change on a 10-point scale ranging from a weak change (1) to very strong (10).
| units on a scale | Diazepam Nasal Spray (Adults) |
|---|---|
| Week 12 | 7.7 ± 2.73 |
| Week 24 | 8.3 ± 0.50 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adults | 0/84 (0%) | 11/84 (13.1%) | 64/84 (76.2%) |
| Adolescents | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| Event | Adults | Adolescents |
|---|---|---|
| Status EpilepticusNervous system disorders | 3/84 | 1/7 |
| MigraineNervous system disorders | 2/84 | 0/7 |
| LeukopeniaBlood and lymphatic system disorders | 1/84 | 0/7 |
| Oesophagitis UlcerativeGastrointestinal disorders | 1/84 | 0/7 |
| VomitingGastrointestinal disorders | 1/84 | 0/7 |
| Otitis MediaInfections and infestations | 1/84 | 0/7 |
| Septic ShockInfections and infestations | 1/84 | 0/7 |
| DehydrationMetabolism and nutrition disorders | 1/84 | 0/7 |
| Diebetes MellitusMetabolism and nutrition disorders | 1/84 | 0/7 |
| Diabetic KetoacidosisMetabolism and nutrition disorders | 1/84 | 0/7 |
| Event | Adults | Adolescents |
|---|---|---|
| Nasal DiscomfortRespiratory, thoracic and mediastinal disorders | 25/84 | 2/7 |
| DysgeusiaRespiratory, thoracic and mediastinal disorders | 15/84 | 0/7 |
| Nasal Mucosal DisorderRespiratory, thoracic and mediastinal disorders | 6/84 | 1/7 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 8/84 | 1/7 |
| Lacrimation increasedEye disorders | 7/84 | 1/7 |
| Throat IrritationRespiratory, thoracic and mediastinal disorders | 7/84 | 0/7 |
| OverdoseInjury, poisoning and procedural complications | 6/84 | 0/7 |
| SomnolenceNervous system disorders | 6/84 | 0/7 |
| Age, Categorical(Participants) | Diazapam Nasal Spray (DZNS) Adults | Diazapam Nasal Spray (DZNS) Adolescents | Total |
|---|---|---|---|
| <=18 years | 7 | 9 | 16 |
| Between 18 and 65 years | 91 | 0 | 91 |
| >=65 years | 1 | 0 | 1 |
| Age, Continuous(years) | Diazapam Nasal Spray (DZNS) Adults | Diazapam Nasal Spray (DZNS) Adolescents | Total |
|---|---|---|---|
| Mean | 34.6 ± 12.58 | 13.4 ± 1.13 | 32.9 ± 13.40 |
| Sex: Female, Male(Participants) | Diazapam Nasal Spray (DZNS) Adults | Diazapam Nasal Spray (DZNS) Adolescents | Total |
|---|---|---|---|
| Female | 48 | 3 | 51 |
| Male | 51 | 6 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Diazapam Nasal Spray (DZNS) Adults | Diazapam Nasal Spray (DZNS) Adolescents | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 8 |
| Not Hispanic or Latino | 93 | 7 | 100 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Diazapam Nasal Spray (DZNS) Adults | Diazapam Nasal Spray (DZNS) Adolescents | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 5 | 0 | 5 |
| Black or African American | 9 | 1 | 10 |
| White | 75 | 8 | 83 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 7 | 0 | 7 |
| Region of Enrollment(Participants) | Diazapam Nasal Spray (DZNS) Adults | Diazapam Nasal Spray (DZNS) Adolescents | Total |
|---|---|---|---|
| United States | 99 | 9 | 108 |
The record gives a start of Dec 2014, a primary completion of Jul 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2018, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diazepam